Cross Validation Assessment of Clinical Performance Characteristics of a Test Table for the Risk of Maternal Autoantibody-Related Autism in High-Risk Populations
Abstract
Background/ObjectivesSpecific combinations of maternal autoantibodies targeting fetal brain proteins are associated with Maternal Autoantibody-Related Autism (MARA), a biologically defined subset of autism. We previously translated a multi-ELISA assay to detect MARA-associated autoantibodies and identify mothers with transcendent levels of specific autoantibody combinations that exceed that of controls and are highly predictive of autism in their offspring. Our objective here was to derive a rule-based classifier, a "test table" of autoantibody pairwise combinations, each with pair-specific thresholds, and to validate its clinical performance characteristics by cross-validation.
MethodsPlasma samples from mothers of 482 autism and 425 typically developing children were analyzed in a clinical lab for previously identified predictive combinations of autoantibodies. Stratified 20-fold cross-validation in all 907 participants assessed test table stability and predictive performance. The most stable test table was retrained on the full cohort to establish optimal thresholds and determine performance. Permutation testing assessed performance relative to chance.
ResultsCross-validated performance showed a mean specificity across folds of 99.8%, an imputed mean PPV of 97.5%, a detection rate of 4.4%, and a positive likelihood ratio (LR+) of 18.5. Applied in-sample to the full cohort, the final test table detected 6.2% of cases with no false positives, giving an upper-range LR+ estimate of 26.5.
ConclusionThe high specificity, PPV, and positive likelihood ratio of this assay support its potential clinical implementation for identifying a subset of mothers at very high risk of having a child with autism, and as a companion diagnostic for interventions targeting the MARA subtype of autism.
Related
- Comprehensive coronary computed tomography angiography assessment in high-altitude diabetic populations: integrating plaque characteristics, pericoronary inflammation, and coronary function
- PROTEOMIC IDENTIFICATION OF NOVEL AUTOANTIBODY TARGETS IN RHEUMATOID ARTHRITIS AND DIAGNOSTIC PERFORMANCE OF TGF-BETA-1-INDUCED PROTEIN AND SERUM AMYLOID A AUTOANTIBODIES
- Beyond Screening Populations: Context-Dependent Performance of Lung Cancer Risk Assessment Strategies in a Diagnostically Enriched Cohort.
- Maternal Autoantibody Combinations as Predictors of Autism Risk: Retrospective Discovery and External Validation in a Prospective Cohort at Increased Risk
- Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol
BibTeX
@misc{wassman2026cross,
title = {{Cross Validation Assessment of Clinical Performance Characteristics of a Test Table for the Risk of Maternal Autoantibody-Related Autism in High-Risk Populations}},
author = {E. R. Wassman and M. Martin and J. Schauer and J. A. Van de Water and M. S. Paul},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.23.26366366},
url = {https://www.medrxiv.org/content/10.64898/2026.10.23.26366366v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Cross Validation Assessment of Clinical Performance Characteristics of a Test Table for the Risk of Maternal Autoantibody-Related Autism in High-Risk Populations
AU - E. R. Wassman
AU - M. Martin
AU - J. Schauer
AU - J. A. Van de Water
AU - M. S. Paul
PY - 2026
DA - 2026/10/23
PB - medRxiv
DO - 10.64898/2026.10.23.26366366
UR - https://www.medrxiv.org/content/10.64898/2026.10.23.26366366v1
AB - Background/ObjectivesSpecific combinations of maternal autoantibodies targeting fetal brain proteins are associated with Maternal Autoantibody-Related Autism (MARA), a biologically defined subset of autism. We previously translated a multi-ELISA assay to detect MARA-associated autoantibodies and identify mothers with transcendent levels of specific autoantibody combinations that exceed that of controls and are highly predictive of autism in their offspring. Our objective here was to derive a rule-based classifier, a "test table" of autoantibody pairwise combinations, each with pair-specific thresholds, and to validate its clinical performance characteristics by cross-validation. MethodsPlasma samples from mothers of 482 autism and 425 typically developing children were analyzed in a clinical lab for previously identified predictive combinations of autoantibodies. Stratified 20-fold cross-validation in all 907 participants assessed test table stability and predictive performance. The most stable test table was retrained on the full cohort to establish optimal thresholds and determine performance. Permutation testing assessed performance relative to chance. ResultsCross-validated performance showed a mean specificity across folds of 99.8%, an imputed mean PPV of 97.5%, a detection rate of 4.4%, and a positive likelihood ratio (LR+) of 18.5. Applied in-sample to the full cohort, the final test table detected 6.2% of cases with no false positives, giving an upper-range LR+ estimate of 26.5. ConclusionThe high specificity, PPV, and positive likelihood ratio of this assay support its potential clinical implementation for identifying a subset of mothers at very high risk of having a child with autism, and as a companion diagnostic for interventions targeting the MARA subtype of autism.
ER -